ANDA 216003, held by Be Pharms. Succinylcholine Chloride.
As of Nov 16, 2026, ANDA 216003 (Succinylcholine Chloride), held by Be Pharms, was first approved by FDA on Feb 7, 2022, with 2 approved supplements and 0 published complete response letters.
Succinylcholine Chloride Injection is indicated in adults and pediatric patients: as an adjunct to general anesthesia to facilitate tracheal intubation to provide skeletal muscle relaxation during surgery or mechanical ventilation.
| Date | Submission | Status | Documents |
|---|---|---|---|
| Feb 7, 2022 | Original application | Approved | None posted |
| Product | Active ingredient | Marketing |
|---|---|---|
| Succinylcholine Chloride20MG/ML · injectable;injection | Succinylcholine Chloride | Rx |
| Feb 22, 2023 | Supplement 3Labeling · Standard review | Approved | None posted |
| Sep 21, 2022 | Supplement 1Labeling · Standard review | Approved | None posted |
| Feb 7, 2022 | Original application | Approved | None posted |
Approvals, supplements, products and documents come from FDA's Drugs@FDA data files, refreshed daily; Drugs@FDA lists approved applications only. Complete response letters are FDA's published letters. Drugs@FDA and FDA complete response letters